Testosterone Isocaproate: A Full Review of the Risks

Testosterone isocaproate is rarely encountered on its own. It appears mainly as one of four esters in blended testosterone preparations, where it occupies the middle of the release curve. Because the ester is simply a delivery mechanism, its risk profile is the risk profile of testosterone itself. Our editorial team reviews what is known about those risks, drawing on clinical trials and endocrine society statements.

What the substance is

Testosterone isocaproate is an ester of testosterone and isocaproic acid, a branched six-carbon fatty acid. The ester makes the molecule more fat-soluble so that it leaves an oil depot in muscle gradually. Enzymes called esterases then cleave the ester in the bloodstream, releasing testosterone identical to the hormone produced by the testes.

Because its chain is intermediate in length, isocaproate releases more slowly than propionate and faster than decanoate. Blended products combine several esters to produce a composite release curve, a formulation approach dating from the 1960s that was intended to reduce injection frequency in hormone replacement.

In the UK, testosterone preparations are prescription-only medicines and are also Class C controlled drugs in Schedule 4 Part II of the Misuse of Drugs Regulations. Supply, sale and importation for others are offences. In sport, testosterone and all its esters are prohibited at all times by the World Anti-Doping Agency.

Licensed indications are confined to male hypogonadism and a small number of specialist uses. Every adverse effect described below is dose-dependent, and the risk profile at supraphysiological amounts is substantially worse than at replacement doses used under supervision.

Cardiovascular and metabolic risks

The best-characterised metabolic change is a fall in high-density lipoprotein cholesterol, often accompanied by a rise in low-density lipoprotein. The effect is modest at replacement doses and pronounced at high doses, and oral 17α-alkylated steroids worsen it further. Unfavourable lipids over years are a recognised contributor to atherosclerosis.

Blood pressure can rise, partly through sodium and fluid retention and partly through effects on vascular tone. Hypertension in a young, otherwise healthy strength athlete is a common finding in clinics that see long-term users, and it frequently goes unrecognised because it is asymptomatic.

Cardiac structure is also affected. Baggish and colleagues (2017) compared long-term users of anabolic-androgenic steroids with non-users using echocardiography and found reduced left ventricular systolic function and impaired diastolic function in users, together with more coronary atherosclerosis on CT. Case series have described cardiomyopathy and sudden cardiac death in young users.

For contrast, the TRAVERSE trial (2023) studied licensed testosterone replacement in more than 5,000 hypogonadal men at elevated cardiovascular risk and found no excess of major adverse cardiac events, though atrial fibrillation and pulmonary embolism were more frequent in the testosterone group. Those findings apply to supervised therapeutic dosing and cannot be extrapolated to high-dose non-medical use.

Blood, hormonal and fertility effects

Testosterone stimulates erythropoiesis. A rising haematocrit is the single most common laboratory abnormality during therapy, and manufacturers' labelling and the Endocrine Society guideline advise monitoring it. Excessive erythrocytosis increases blood viscosity and is associated with thrombotic events, so clinicians intervene when it exceeds defined thresholds.

Exogenous testosterone also suppresses the hypothalamic–pituitary–testicular axis. Luteinising hormone and follicle-stimulating hormone fall, intratesticular testosterone collapses and spermatogenesis stops. Testicular volume decreases, and azoospermia is common. Rahnema and colleagues (2014) described anabolic-steroid-induced hypogonadism and noted that recovery can take many months and is not guaranteed.

Aromatisation of testosterone to oestradiol produces further effects. At high hormone levels, gynaecomastia and fluid retention become more likely. Conversion to dihydrotestosterone drives acne, oily skin, accelerated male-pattern hair loss in genetically predisposed individuals and prostate growth.

In women, androgens cause virilisation: deepening of the voice, facial hair growth, clitoromegaly and menstrual disruption. Voice changes in particular are generally irreversible, a point emphasised in reviews of androgen use in female athletes.

Psychological effects and dependence

Mood changes are among the most frequently reported subjective effects. Pope and colleagues conducted blinded studies in the 1990s showing that a minority of participants given high doses of testosterone developed marked hypomanic or aggressive symptoms, while most showed little change. The susceptibility appears highly individual.

Withdrawal is a distinct problem. When exogenous hormone stops and endogenous production has not recovered, users may experience low mood, fatigue, loss of libido and in some cases clinically significant depression. This state can drive renewed use, establishing a cycle that resembles dependence.

Kanayama, Pope and colleagues have described a dependence syndrome in a substantial subset of long-term users, characterised by continued use despite harm and difficulty stopping. Body-image disorders, including muscle dysmorphia, are frequently comorbid.

These effects are often dismissed as anecdote, but they have consistent support in the literature and are a legitimate reason to seek help from a GP or a substance-use service, which in the UK can be accessed without judgement.

Injection-related and product-quality risks

Any intramuscular injection carries risks of pain, bleeding, nerve injury and infection. Local complications reported in users include sterile abscesses from oil irritation, bacterial abscesses requiring surgical drainage, cellulitis and, rarely, necrotising infection. Oil embolism and cough reactions have also been described.

Needle sharing transmits bloodborne viruses. Public Health England surveys of people who inject image- and performance-enhancing drugs have found appreciable rates of hepatitis B, hepatitis C and HIV markers in this group, which is why needle and syringe programmes in the UK explicitly serve them.

Product quality is a further hazard. Analyses of seized and market-sourced products repeatedly find wrong concentrations, substituted substances, absent active ingredients and contamination. A user has no reliable way of knowing what is in an unlicensed vial.

The combination of unknown product, unsupervised dosing and absent monitoring is what turns a manageable clinical risk into an unpredictable one.

Conclusions of the editorial team

Testosterone isocaproate is not a distinct drug with its own side-effect list; it is testosterone with a mid-length ester attached. Its risks are those of androgen exposure, and they scale steeply with dose and duration.

Under medical supervision for diagnosed hypogonadism, testosterone has an acceptable and well-monitored risk profile. Outside that setting, the documented hazards include adverse lipid changes, hypertension, cardiac remodelling, erythrocytosis, prolonged or permanent suppression of fertility, irreversible virilisation in women, mood disturbance and dependence.

Anyone with symptoms suggestive of low testosterone should seek blood tests and an endocrinology or andrology opinion rather than self-treating, and anyone already using these substances should talk to a clinician about monitoring and stopping safely.

Our related articles cover haematocrit and blood viscosity in athletes, recovery of the hypothalamic–pituitary–testicular axis, and what full blood count and lipid panels reveal in strength sports.

References

1. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
3. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
4. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117.
5. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
6. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966–1978.
7. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry. 2000;57(2):133–140.